Literature DB >> 3729362

Aztreonam concentration in abdominal tissues and bile.

R E Condon, L T Friedhoff, C E Edmiston, B Levinson.   

Abstract

Abdominal tissue, serum, and bile samples were obtained from 37 patients given a single, 2-g intravenous infusion of aztreonam immediately prior to an elective abdominal operation. Samples were obtained at 0 to 6 h after dosing. Mean concentrations in tissues and fluids and specimen/serum rations are reported. Levels in tissue and bile exceeded the reported MICs for 90% of most members of the family Enterobacteriaceae for up to 6 h.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729362      PMCID: PMC180509          DOI: 10.1128/AAC.29.6.1101

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro activities of Ro 17-2301 and aztreonam compared with those of other new beta-lactam antibiotics against clinical isolates of Pseudomonas aeruginosa.

Authors:  W W Ng; P Y Chau; Y K Leung; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

Review 2.  The excretion of antibiotics by the biliary tract.

Authors:  H Nagar; S A Berger
Journal:  Surg Gynecol Obstet       Date:  1984-06

3.  Concentrations of cefamandole and cefsulodin in serum, heart valves, subcutaneous tissue, and muscle of patients undergoing open-heart surgery.

Authors:  F D Daschner; B Metz; G Spillner; W Buzello; V Schlosser
Journal:  J Infect Dis       Date:  1980-08       Impact factor: 5.226

4.  Aztreonam concentrations in human prostatic tissue.

Authors:  P O Madsen; R Dhruv; L T Friedhoff
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  Comparative activities of aztreonam and cefotaxime against Escherichia coli and Bacteroides spp. in pure and mixed cultures.

Authors:  F Soriano; M C Ponte
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

6.  In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.

Authors:  M A Buesing; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

7.  Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

Authors:  R B Sykes; D P Bonner; K Bush; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.

Authors:  S C Aronoff; J D Klinger
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

9.  High-pressure liquid chromatographic analysis of aztreonam in sera and urine.

Authors:  F G Pilkiewicz; B J Remsburg; S M Fisher; R B Sykes
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

10.  Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.

Authors:  E A Swabb; A A Sugerman; T B Platt; F G Pilkiewicz; M Frantz
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.